S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Cocrystal Pharma Stock Forecast, Price & News

+0.15 (+18.29%)
(As of 11/26/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
3.33 million shs
Average Volume
6.55 million shs
Market Capitalization
$94.54 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive COCP News and Ratings via Email

Sign-up to receive the latest news and ratings for Cocrystal Pharma and its competitors with MarketBeat's FREE daily newsletter.

Cocrystal Pharma logo

About Cocrystal Pharma

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded in 2008 and is headquartered in Bothell, WA.


Short Interest in Cocrystal Pharma, Inc. (NASDAQ:COCP) Drops By 61.1%
November 17, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$2.01 million
Book Value
$0.83 per share


Net Income
$-9.65 million
Pretax Margin




Free Float
Market Cap
$94.54 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.70 out of 5 stars

Medical Sector

938th out of 1,391 stocks

Pharmaceutical Preparations Industry

443rd out of 669 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Cocrystal Pharma (NASDAQ:COCP) Frequently Asked Questions

Is Cocrystal Pharma a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cocrystal Pharma stock.
View analyst ratings for Cocrystal Pharma
or view top-rated stocks.

How has Cocrystal Pharma's stock price been impacted by COVID-19 (Coronavirus)?

Cocrystal Pharma's stock was trading at $1.26 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, COCP stock has decreased by 23.0% and is now trading at $0.97.
View which stocks have been most impacted by COVID-19

Are investors shorting Cocrystal Pharma?

Cocrystal Pharma saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 318,200 shares, an increase of 24.0% from the October 31st total of 256,600 shares. Based on an average trading volume of 794,700 shares, the short-interest ratio is currently 0.4 days. Currently, 0.4% of the company's stock are short sold.
View Cocrystal Pharma's Short Interest

When is Cocrystal Pharma's next earnings date?

Cocrystal Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, March 16th 2022.
View our earnings forecast for Cocrystal Pharma

How were Cocrystal Pharma's earnings last quarter?

Cocrystal Pharma, Inc. (NASDAQ:COCP) issued its earnings results on Monday, November, 15th. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04).
View Cocrystal Pharma's earnings history

What price target have analysts set for COCP?

2 Wall Street analysts have issued 12-month price objectives for Cocrystal Pharma's shares. Their forecasts range from $4.00 to $5.00. On average, they anticipate Cocrystal Pharma's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 363.9% from the stock's current price.
View analysts' price targets for Cocrystal Pharma
or view top-rated stocks among Wall Street analysts.

Who are Cocrystal Pharma's key executives?

Cocrystal Pharma's management team includes the following people:
  • Sam Lee, President & Co-Chief Executive Officer
  • James Joseph Martin, Co-Chief Executive Officer, CFO & Secretary
  • Luz Pascual, Vice President-Clinical Development

What other stocks do shareholders of Cocrystal Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Moderna (MRNA), Momo (MOMO), Intra-Cellular Therapies (ITCI), Impala Platinum (IMPUY), GenMark Diagnostics (GNMK), Gevo (GEVO), Auxly Cannabis Group (CBWTF), Bionano Genomics (BNGO), Blink Charging (BLNK) and Bilibili (BILI).

What is Cocrystal Pharma's stock symbol?

Cocrystal Pharma trades on the NASDAQ under the ticker symbol "COCP."

Who are Cocrystal Pharma's major shareholders?

Cocrystal Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.08%), BlackRock Inc. (1.14%), Geode Capital Management LLC (0.82%), Mariner LLC (0.31%), LPL Financial LLC (0.18%) and Goldman Sachs Group Inc. (0.16%). Company insiders that own Cocrystal Pharma stock include Raymond F Schinazi and Richard C Pfenniger, Jr.
View institutional ownership trends for Cocrystal Pharma

Which major investors are selling Cocrystal Pharma stock?

COCP stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Dimensional Fund Advisors LP, HighTower Advisors LLC, and BlackRock Inc..
View insider buying and selling activity for Cocrystal Pharma
or view top insider-selling stocks.

Which major investors are buying Cocrystal Pharma stock?

COCP stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Millennium Management LLC, Mariner LLC, Two Sigma Advisers LP, LPL Financial LLC, Goldman Sachs Group Inc., Barclays PLC, and Raymond James Financial Services Advisors Inc..
View insider buying and selling activity for Cocrystal Pharma
or or view top insider-buying stocks.

How do I buy shares of Cocrystal Pharma?

Shares of COCP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cocrystal Pharma's stock price today?

One share of COCP stock can currently be purchased for approximately $0.97.

How much money does Cocrystal Pharma make?

Cocrystal Pharma has a market capitalization of $94.54 million and generates $2.01 million in revenue each year. The company earns $-9.65 million in net income (profit) each year or ($0.13) on an earnings per share basis.

How many employees does Cocrystal Pharma have?

Cocrystal Pharma employs 13 workers across the globe.

What is Cocrystal Pharma's official website?

The official website for Cocrystal Pharma is www.cocrystalpharma.com.

Where are Cocrystal Pharma's headquarters?

Cocrystal Pharma is headquartered at 19805 N. CREEK PARKWAY, BOTHELL WA, 98011.

How can I contact Cocrystal Pharma?

Cocrystal Pharma's mailing address is 19805 N. CREEK PARKWAY, BOTHELL WA, 98011. The company can be reached via phone at (786) 459-1831 or via email at [email protected].

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.